

**REMARKS**

An Office Action was issued on March 12, 1999 in the parent case, U.S. Application Serial No. 08/702,502. Applicants choose to pursue further prosecution of the '502 subject matter through entry of the Rule 53(b) continuation application and this Preliminary Amendment. Therefore, a petition to extend time for responding to the '502 application Office Action is being submitted separately in the '502 application file in order to keep the '502 application pending through at least Monday, September 13, 1999.

The specification was amended to add an Abstract of the Disclosure as new page 148. No new matter is added by introduction of the Abstract.

Claims 1, 18, 22, 24, 35, 39, 41, 42 and 44 were amended to more particularly point out and distinctly claim the subject matter Applicants regard as their invention.

Claim 2 was amended herein to delete recitation of cancer vaccine and applications.

Applicants reserve the right to pursue canceled subject matter in a later continuing application.

No new matter is added by these claim amendments.

The claims are now in better form for examination and allowance. Early action to that end is earnestly solicited. The Examiner is invited to contact the undersigned attorney if clarification is required on any aspect of this response, or if any of the claims are considered to require further amendment to be placed in condition for allowance.

Respectfully submitted,



J. Mark Hand  
Reg. No. 36,545  
Attorney for Applicants  
Merck & Co., Inc.  
P.O. Box 2000  
Rahway, NJ 07065-0907  
(732) 594-3905

Date: SEPTEMBER 10, 1999